ELU42 Topical Spray

Small molecule

EEluciderm Inc

ELU42 Topical Spray is one of 34 small molecule programs targeting Diabetic Foot. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic FootActive, not recruiting

Diabetic FootPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

210 competitors in Diabetic Foot

#DrugCompanyPhaseTrials

Isordil

AstraZeneca

Phase 3

1 2

Zyvox

Pfizer

Phase 3

1 3

Cysteine Hydrochloride

Novartis

Phase 3

1 4

Cubicin

BBaxter Healthcare Corporation

Phase 3

1 5

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 6

Tygacil

PPrism Pharmaceuticals

Phase 3

1 7

Urokinase

Mmedac GmbH

Phase 3

3 8

Bemiparin

RRovi Pharmaceuticals Laboratories

Phase 3

1 9

Biochaperone Combo

AAdocia

Phase 3

1 10

Beta-Glucan

BBiotec Pharmacon ASA

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetic Foot1 trial

Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers

Recruiting·EEluciderm Inc·Phase 1/2·NCT07396376·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ELU42 Topical Spray. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ELU42 Topical Spray compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ELU42 Topical Spray. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eluciderm Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: EEluciderm Inc

ELU42 Topical Spray

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diabetic Foot1 trial

References

Drug Info

Quick Facts

Related News